Cenra Inc (3716) Fair Value & Analysis
Healthcare · TW · Market cap 5.0B TWD
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from 39.73 TWD to 39.55 TWD (−0.5%) since Jul 9, 2026. Share price +0.4% over the past month.
A solid business, screening 12% undervalued on our models.
What matters now
- A fairly wide model range (26.43 TWD to 51.09 TWD) leaves room in how you read the outcome.
- Our model range runs from 26.43 TWD (bear) to 51.09 TWD (bull), base 39.55 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 61/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 19.37 TWD – 40.54 TWD · fair‑value band 26.43 TWD – 51.09 TWD · the 35.35 TWD price screens below the 39.55 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Cenra Inc (3716) currently trades at 35.35 TWD, while our model-based Fair Value estimate is 39.55 TWD, implying the stock looks roughly 11.9% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Cenra Inc generated revenue of 8.5B TWD at a net margin of 4.4%. Revenue declined 1.2% year over year. It earns a return on equity of 4.8%. Net debt stands at 1.9B TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 26.43 TWD (bear case) to 51.09 TWD (bull case); at 35.35 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 12% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 12%, 3716 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth DCF (43.67 TWD) versus Dividend Discount (10.03 TWD). Highest evidence: Growth DCF (80).
Notify me when 3716 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 65
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
Full company description
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development, scale-up, and regulatory support; distribution, and marketing for prescription drugs, OTC products, health supplements, personal care products, and medical devices;home care, caregiver training, and consulting for elderly support; develops and manufactures veterinary pharmaceuticals, and animal health products for livestock and companion animals and offers CDMO services for animal health partners. Cenra Inc. was founded in 2024 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cenra Inc reported revenue of 8.6B TWD in FY2025 versus 7.9B TWD in FY2021, a compound +1.9%/yr. Reported net income was 300M TWD in FY2025, compounding −12.7%/yr from FY2021.
Watch 3716: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Cenra Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cenra Inc (3716) overvalued or undervalued?
What is the fair value of 3716?
What is the quality score of 3716?
What is the revenue of Cenra Inc (3716)?
What is the net profit margin of 3716?
Does Cenra Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cenra Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.